Cannalean Biotech

CBD-based Solutions for Treating Dyslipidemia

CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia.

CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company’s preliminary results show the effect of the formulation on cholesterol and triglyceride

%d bloggers like this: